High-throughput screening approaches for investigating drug metabolism and pharmacokinetics

1. High-throughput screening approaches have been adopted throughout the pharmaceutical industry to aid in the rapid discovery of new chemical entities. Because it is now well recognized that the selection of a robust candidate requires a balance of potency, safety and pharmacokinetics, the role of drug metabolism departments has widened from their traditional one of supporting drug development to include the screening of compounds during the discovery process. To put drug metabolism and pharmacokinetic (DMPK) studies in context, the evolving role of DMPK screening in the drug discovery strategy of pharmaceutical companies will be discussed and a generalized approach will be presented. 2. With the increasing numbers of compounds requiring screening, DMPK optimization methods have had to be adapted for high throughput. There have been many developments in this field over the past decade and this review will focus on the high-throughput DMPK screening methodologies used today and in the recent past. 3. In vitro and in silico (computer-based) methods have proven most amenable to high-throughput approaches and these will form the bulk of the review, but some advances with in vivo methods will also be discussed. As there has been a vast increase in published material on the topic of high-throughput DMPK methodologies in the past 10 years, it would be impossible to cover every method in detail, so this review will concentrate on the key areas and refer the reader to other, more detailed reviews wherever possible. 4. Most high-throughput methods would not be possible without the enabling technologies of computing, automation, new sample preparation technologies, and highly sensitive and selective detection systems, and these will also be reviewed. 5. The advantages and disadvantages of the screening methods will be presented, in particular the issue of handling the false-positives and-negatives that arise. 6. In concluding the review, future developments in this field will be discussed along with key issues that will need to be addressed.

[1]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[2]  D. Wu,et al.  High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk solid phase extraction plate for the sample preparation. , 1998, Rapid communications in mass spectrometry : RCM.

[3]  Thomas J. Raub,et al.  A General, Wide-Range Spectrofluorometric Method for Measuring the Site-Specific Affinities of Drugs toward Human Serum Albumin , 1995 .

[4]  A M Richard,et al.  Commercial toxicology prediction systems: a regulatory perspective. , 1998, Toxicology letters.

[5]  I. Wilson,et al.  Rapid multi-component detection of fluorinated drug metabolites in whole urine from a ‘cassette’ dose study using high resolution 19F NMR spectroscopy , 1999 .

[6]  M D Todd,et al.  Emerging technologies for accelerated toxicity evaluation of potential drug candidates. , 1999, Current opinion in drug discovery & development.

[7]  M H Tarbit,et al.  High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. , 1998, Current opinion in chemical biology.

[8]  T. Olah,et al.  The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.

[9]  Pravin Chaturvedi,et al.  Design principles for orally bioavailable drugs , 1996 .

[10]  M. Abraham,et al.  The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. , 1999, Journal of pharmaceutical sciences.

[11]  D. Surry,et al.  High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[13]  A Tropsha,et al.  Recent trends in computer-aided drug discovery. , 2000, Current opinion in drug discovery & development.

[14]  W. Rubas,et al.  A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.

[15]  W. Pardridge,et al.  CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport , 1998, Journal of neurochemistry.

[16]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Crespi Assessing the potential for drug-drug interactions in an accelerated throughput mode. , 1999, Pharmaceutical science & technology today.

[18]  Peter C. Jurs,et al.  Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure , 1998, J. Chem. Inf. Comput. Sci..

[19]  R. Norton,et al.  Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. , 1998, JAMA.

[20]  U Norinder,et al.  Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. , 1998, Journal of pharmaceutical sciences.

[21]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[22]  P. Morgan,et al.  Role of transport proteins in drug absorption, distribution and excretion , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  T. Andersson,et al.  Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  J. Bolton,et al.  Metabolic screening using on-line ultrafiltration mass spectrometry. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[25]  Ada M. Herrera,et al.  Microdialysis Sampling for Determination of Plasma Protein Binding of Drugs , 1990, Pharmaceutical Research.

[26]  A. Li,et al.  Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. , 1997, Chemico-biological interactions.

[27]  P. Woollard,et al.  Cassette dosing: rapid in vivo assessment of pharmacokinetics , 1998 .

[28]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[29]  A. Beresford,et al.  ADME/PK as part of a rational approach to drug discovery. , 2000, Drug discovery today.

[30]  A. D. Rodrigues,et al.  [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[31]  S. Ball,et al.  Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Amess,et al.  Proteomics: a major new technology for the drug discovery process. , 1999, Drug discovery today.

[33]  S. Ekins,et al.  Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[34]  S. Kliewer,et al.  Use of the nuclear receptor PXR to predict drug interactions. , 2000, Toxicology.

[35]  Johnson,et al.  Predicting human safety: screening and computational approaches. , 2000, Drug discovery today.

[36]  M. Gross,et al.  Fourier transform mass spectrometry. , 1984, Science.

[37]  F. Gonzalez,et al.  Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. , 1996, Molecular pharmacology.

[38]  D. Livingstone,et al.  Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. , 2000, European journal of medicinal chemistry.

[39]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[40]  C. Pidgeon,et al.  IAM chromatography: an in vitro screen for predicting drug membrane permeability. , 1995, Journal of medicinal chemistry.

[41]  H. Kusuhara,et al.  Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). , 2001, Drug discovery today.

[42]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[43]  M Bajpai,et al.  High-throughput screening for lead optimization: a rational approach. , 2000, Current opinion in drug discovery & development.

[44]  Ferenc Darvas,et al.  Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries , 2000, J. Chem. Inf. Comput. Sci..

[45]  M K Bayliss,et al.  High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.

[46]  J Taskinen Prediction of aqueous solubility in drug design. , 2000, Current opinion in drug discovery & development.

[47]  D. Lewis,et al.  A prospective toxicity evaluation (COMPACT) on 40 chemicals currently being tested by the National Toxicology Program. , 1990, Mutagenesis.

[48]  F. Gonzalez,et al.  Analysis of human cytochrome P450 catalytic activities and expression. , 1992, The Tohoku journal of experimental medicine.

[49]  P Ruelle,et al.  The hydrophobic effect. 2. Relative importance of the hydrophobic effect on the solubility of hydrophobes and pharmaceuticals in H-bonded solvents. , 1998, Journal of pharmaceutical sciences.

[50]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[51]  Yukio Tominaga,et al.  Comparative study of class data analysis with PCA-LDA, SIMCA, PLS, ANNs, and k-NN , 1999 .

[52]  K. Adkison,et al.  Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. , 1997, Journal of medicinal chemistry.

[53]  A. Monks,et al.  Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. , 1999, Biochemical pharmacology.

[54]  Chao-pin Lee,et al.  Selection of development candidates based on in vitro permeability measurements , 1997 .

[55]  J B Houston,et al.  Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[56]  H. Waterbeemd,et al.  Comparison of passive drug transport through Caco-2 cells and artificial membranes , 1997 .

[57]  B. W. Penman,et al.  Development of Caco-2 Cells Expressing High Levels of cDNA-Derived Cytochrome P4503A4 , 1996, Pharmaceutical Research.

[58]  A. Li,et al.  Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.

[59]  U Norinder,et al.  Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[60]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[61]  M H Tarbit,et al.  Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  R. Cooks,et al.  Quadrupole Mass Filters and Quadrupole Ion Traps , 1997 .

[63]  Ronald T. Borchardt,et al.  Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides , 1994, Pharmaceutical Research.

[64]  M. Hoshen,et al.  The role of ligand-binding proteins in increasing the transcellular flux of metabolites, in particular that of calcium, bilirubin, and fatty acids , 1996 .

[65]  B. Walther,et al.  Rapid assessment of drug metabolism in the drug discovery process. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[66]  Han van de Waterbeemd,et al.  Estimation of Caco‐2 Cell Permeability using Calculated Molecular Descriptors , 1996 .

[67]  G M Pacifici,et al.  Methods of Determining Plasma and Tissue Binding of Drugs , 1992, Clinical pharmacokinetics.

[68]  D. E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[69]  D. Scarpelli,et al.  Uptake of N-nitrosobis(2-oxopropyl)amine by isolated rat and hamster hepatocytes: species differences and evidence for an active carrier-mediated transport process. , 1988, Carcinogenesis.

[70]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[71]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[72]  C. Crespi Higher-throughput screening with human cytochromes P450. , 1999, Current opinion in drug discovery & development.

[73]  Y. Sugiyama,et al.  Primary active transport of organic anions on bile canalicular membrane in humans. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[74]  G. Caldwell Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. , 2000, Current opinion in drug discovery & development.

[75]  S. L. Dixon,et al.  LASSOO: a generalized directed diversity approach to the design and enrichment of chemical libraries. , 1999, Journal of medicinal chemistry.

[76]  P. Veng‐Pedersen,et al.  Quantitative structure-pharmacokinetic relationships for systemic drug distribution kinetics not confined to a congeneric series. , 1994, Journal of pharmaceutical sciences.

[77]  S. Walker,et al.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.

[78]  Mark T. D. Cronin Computer‐aided Prediction of Drug Toxicity in High Throughput Screening , 1998 .

[79]  R. Plumb,et al.  Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. , 1998, Rapid communications in mass spectrometry : RCM.

[80]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[81]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[82]  C. Wolf,et al.  Use of Transgenic Animals in Understanding Molecular Mechanisms of Toxicity * , 1998, The Journal of pharmacy and pharmacology.

[83]  K. Hayashi,et al.  Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. , 1990, The Journal of biological chemistry.

[84]  P A Carrupt,et al.  Evaluation and Prediction of Drug Permeation , 1999, The Journal of pharmacy and pharmacology.

[85]  R J Riley,et al.  Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[86]  C. Hop,et al.  Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.

[87]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[88]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[89]  Evans,et al.  Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.

[90]  D. R. Hawkins,et al.  Use and value of metabolism databases. , 1999, Drug discovery today.

[91]  S. Fulton,et al.  Ultrafiltration vs Equilibrium Dialysis for Determination of Free Fraction , 1984, Clinical pharmacokinetics.

[92]  P J Sinko Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. , 1999, Current opinion in drug discovery & development.

[93]  D. Robertson,et al.  High-throughput toxicology: practical considerations. , 2000, Current opinion in drug discovery & development.

[94]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[95]  R. S. Thomas,et al.  Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. , 1998, Environmental health perspectives.

[96]  J. Henion,et al.  Sample preparation for LC/MS/MS: analyzing biological and environmental samples. , 1998, Analytical chemistry.

[97]  P. Swaan,et al.  Molecular determinants of recognition for the intestinal peptide carrier. , 1997, Journal of pharmaceutical sciences.

[98]  G. Grass,et al.  Simulation models to predict oral drug absorption from in vitro data , 1997 .

[99]  R. A. Coleman,et al.  Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[100]  G Folkers,et al.  Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[101]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[102]  Walter A. Korfmacher,et al.  HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .

[103]  N. Olejnik,et al.  Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[104]  L. Wienkers,et al.  Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[105]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[106]  M. Tarbit,et al.  A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[107]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[108]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[109]  T. Kennedy Managing the drug discovery/development interface , 1997 .

[110]  Walter A. Korfmacher,et al.  Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability. , 1999, Rapid communications in mass spectrometry : RCM.

[111]  Walter A. Korfmacher,et al.  Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .

[112]  A. Seelig A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[113]  A George The design and molecular modeling of CNS drugs. , 1999, Current opinion in drug discovery & development.

[114]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[115]  Thomas A. Baillie,et al.  The Impact of Drug Metabolism in Contemporary Drug Discovery: New Opportunities and Challenges for Mass Spectrometry , 2000 .

[116]  B. Kennedy,et al.  Refinement of an in vitro cell model for cytochrome P450 induction. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[117]  P. Worboys,et al.  Implications and consequences of enzyme induction on preclinical and clinical drug development , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[118]  D. Egan,et al.  Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. , 1993, Journal of medicinal chemistry.

[119]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[120]  James L. Winkler,et al.  Accessing Genetic Information with High-Density DNA Arrays , 1996, Science.